---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293964680.md"
description: "Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure."
datetime: "2026-07-27T18:16:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293964680.md)
  - [en](https://longbridge.com/en/news/293964680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293964680.md)
generator: "portal-rs"
---

# 

Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure.

### Related Stocks

- [GOSS.US](https://longbridge.com/en/quote/GOSS.US.md)

## Related News & Research

- [Gossamer Bio announces $250m in funding to advance seralutinib](https://longbridge.com/en/news/296771347.md)
- [Peptide innovator says the drug class is due for a rethink](https://longbridge.com/en/news/297803292.md)
- [10:16 ET/C O R R E C T I O N -- Hiperbaric/](https://longbridge.com/en/news/297531783.md)
- [Alumis says Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus misses primary endpoint](https://longbridge.com/en/news/297644348.md)
- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**